Tezacaftor
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Tezacaftor: From Cystic Fibrosis to HIV Infectious Disease
One-Sentence Summary
Tezacaftor is a CFTR corrector originally developed for cystic fibrosis, used to correct defective CFTR protein folding. The TxGNN model predicts it may be effective for HIV infectious disease, but currently no clinical trials and no publications support this direction — this is a model-prediction-only signal with no mechanistic rationale identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indication data on file) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.24% |
| Evidence Level | L5 |
| Germany Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Tezacaftor is a CFTR corrector class drug, used to correct misfolded CFTR (cystic fibrosis transmembrane conductance regulator) protein and restore chloride channel function at the cell surface — its established role is in cystic fibrosis management.
There is no known mechanistic link between CFTR channel correction and HIV viral replication or host immune pathways. The repurposing rationale provided alongside this prediction explicitly states that no plausible mechanistic hypothesis can be established, and this is reinforced by the complete absence of supporting clinical trials or literature.
This prediction should be treated as a raw computational signal from the TxGNN model only, not as a biologically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Germany Market Information
This drug is not currently marketed in Germany, and no authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications and DDI data are currently unavailable — flagged as a Blocking data gap, preventing S1 safety pre-assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5, no clinical trials, no literature, no established mechanistic link), and a Blocking data gap exists for TFDA label safety data — this combination does not meet the threshold to proceed.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (Blocking gap — required before any S1 safety evaluation)
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- At least preclinical/mechanistic evidence linking CFTR correction to HIV pathophysiology before pursuing further evidence collection
- Original approved indication data to establish baseline drug profile
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.